Childhood cancer survival rates in two South African units by Stones, David K et al.
RESEARCH
501       July 2014, Vol. 104, No. 7
Childhood cancer is uncommon, representing 
1  -  10% of all cancers reported globally.[1] Globally, 
about 160 000 new cases of childhood cancer 
are diagnosed annually,[2] 13 000 in children and 
adolescents (<20 years) living in the USA. The 
annual average age-adjusted incidence rate in the USA is 158/million 
children.[3] Most childhood cancers (~60%) occur in low- and 
middle-income countries where there is limited access to therapy, 
resulting in poor survival rates.[1,4] 
Information about childhood cancer in Africa is lacking, as there 
are few formal cancer registries across the continent. The annual 
incidence of childhood cancer was estimated to be between 33.4 and 
47.2/million between 2003 and 2007.[5] The age-standardised annual 
incidence for all childhood malignancies has been estimated at 87.8 
and 62.6/million in the Western Cape and Free State provinces of 
South Africa (SA), respectively (Stefan DC et al., childhood cancer 
incidence in South Africa, 1987 - 2007, unpublished data). Increased 
resources, improved care and ongoing research have resulted in 
a consistent improvement in survival of children with cancer in 
developed countries, with the 5-year survival rate of children and 
adolescents in the USA approaching 80% and a mortality rate of 
2.8/100 000.[2] Similar results are reported from Europe, with the 
3-year survival rate for all childhood cancers being 81%.[6]
Determinants of mortality and survival in children in the deve-
loping world (including Africa) differ markedly from those in the 
developed world. Survival rates of children with cancer in developing 
countries are far lower than those in the developed world.[4] Deaths 
from paediatric cancer often go unreported, so the true mortality rate 
is unknown.
There are many obstacles to early diagnosis and effective treatment 
of childhood cancer in Africa. Limited resources, late presentation of 
disease,[7] co-morbid infections (such as HIV) and malnutrition are 
among the barriers preventing improvement in survival
Methods
A retrospective demographic analysis of all children aged 0 - 15 
years diagnosed with a malignancy between 1 January 1987 and 
31 December 2011 in two SA paediatric oncology units (POUs) 
(Universitas Hospital Academic Complex (UHAC) in Bloemfontein, 
Free State, and Tygerberg Hospital in Cape Town, Western Cape) 
was performed. Both units have dedicated POUs admitting children 
referred from the large surrounding areas they serve.
Tygerberg Hospital is a tertiary hospital located in Cape Town, 
serving the eastern metropolitan region of Cape Town and the 
north-eastern districts of the Western Cape. The hospital provides 
healthcare to over 3.6 million people (2.4 million children) and is the 
largest hospital in the Western Cape and the second-largest in SA. 
The POU admits on average 50 - 60 new patients per year, with an 
average hospital stay of 5 days per admission.
The Universitas Hospital Academic Complex (UHAC) in 
Bloemfontein provides cancer care to over 1.5 million children. It is 
the referral POU for the whole of the Free State and Northern Cape 
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Introduction. Childhood cancer is relatively rare, but there is a very good chance of cure. While overall survival rates of >70% are reported 
from developed countries, survival is much less likely in developing countries and unknown in many countries in Africa.
Objective. To analyse survival rates of childhood cancers in two South African paediatric oncology units.
Methods. This retrospective review included all children (0 - 15 years) admitted with a malignancy at two paediatric oncology units 
(Universitas Hospital Academic Complex in Bloemfontein, Free State, and Tygerberg Hospital in Cape Town, Western Cape) between 1987 
and 2011. The protocols used in the units were similar, and all the diagnoses were confirmed histologically.
Results. There were 3  241 children, 53.5% of whom were males. Median follow-up was 17 months. The most common cancers were 
leukaemia (25.0%), brain tumours (19.5%), lymphoma (13.0%) and nephroblastoma (10.0%). The prevalences of neuroblastoma and 
retinoblastoma were similar at 5.8% and 5.7%, respectively. Overall survival was calculated to be 52.1%. Lymphoma and nephroblastoma 
had the highest survival rates at 63.9% and 62.6%, respectively. Brain tumours had the lowest survival rate at 46.4%. A comparison between 
ethnic groups showed white children to have the highest survival rate (62.8%); the rate for children of mixed racial origin was 53.8% and 
that for black children 48.5%.
Conclusions. Overall survival rates for children admitted to two paediatric cancer units in South Africa were lower than data published 
from developed countries, because many children presented with advanced disease. New strategies to improve cancer awareness are urgently 
required.
S Afr Med J 2014;104(7):501-504. DOI:10.7196/SAMJ.7882
RESEARCH
502       July 2014, Vol. 104, No. 7
provinces, as well as some areas of both the North West and Eastern 
Cape provinces and Lesotho. This unit sees approximately 100 new 
oncology patients per year.
Data for this study were obtained from the children’s tumour 
registries at the respective POUs and cross-checked with the South 
African Paediatric Tumor Registry. The registries of both units are 
similar, collect the same information and are part of the SA Paediatric 
Tumour Registry. Classification of childhood cancers in the registry 
is based on standards set by the International Classification of 
Childhood Cancers, 3rd edition.[8]
The protocols used in the two units were similar. The National 
Health Laboratory Service confirmed the histological diagnosis of 
malignancy in all cases where samples were available. In only a few 
cases (e.g. brainstem glioma) was diagnosis made on the clinical 
findings and relevant imaging, without histological studies.
The following variables were extracted and entered into a 
Microsoft Excel worksheet: date of birth, diagnosis, age at diagnosis, 
gender, ethnicity, HIV status, date last seen, and outcome at the end 
of the study.
SA has an ethnically diverse population, broadly classified as black, 
white and of mixed racial ancestry. The Western Cape population is 
32.9% black, 48.8% mixed ancestry and 15.7% white (with 1% Asian/
Indian). In the Free State 87.6% are black, 3.1% of mixed ancestry, 
8.7% white and 0.4% Asians/Indians.[9]
All children under 15 years of age were included. Disease was 
staged according to international guidelines. Survival was correlated 
with the stage of the disease and the ethnic group to which each 
patient belonged.
The five most common cancers were leukaemia, brain tumours, 
lymphoma, nephroblastoma and retinoblastoma. Nephroblastoma 
and retinoblastoma were further analysed with regard to survival 
rates, stage and patient ethnic groups. The staging of nephroblastoma 
was based on abdominal ultrasound and computed tomography (CT) 
of the abdomen and, if indicated, of the chest. Magnetic resonance 
imaging (MRI) was done in selected cases to facilitate surgery. The 
staging of retinoblastoma included ophthalmological examination, 
cerebrospinal fluid (CSF) analysis, bone marrow examination and a 
brain CT scan or MRI.
All children were followed up from the date of diagnosis until 
31 December 2012, or until they died or were lost to follow-up. 
Outcomes were defined as overall survival at 1, 3 and 5 years. The 
dates on which patients died or were last seen were documented. 
Patients who were lost to follow-up, either while on treatment or after 
treatment, were included in the analysis as censored observations.
Patients from the two POUs were analysed both together 
and separately, to compare survival rates for the most common 
malignancies encountered. Kaplan-Meier curves were constructed 
for each comparison, and where possible median survival time and 
95% confidence intervals (CIs) were reported. Where cumulative 
survival probability did not drop below 50%, mean survival times 
were reported. Log-rank tests were used to compare groups in 
terms of survival times. All calculations were performed using SPSS 
software (IBM SPSS Statistics, version 21). A p-value of <0.05 was 
considered statistically significant.
Ethics approval was obtained from the human ethics research 
committees of the two participating centres. Confidentiality was 
maintained by using de-identified data throughout.
Results
The initial database included 3 292 children diagnosed with malig-
nancy from both units. Excluded from the analysis were ten children 
who were missing at the end-date of their follow-up period, so 
survival periods could not be calculated; 36 who died before 
receiving treatment or had no outcome information; one whose 
ethnic background was not recorded, and four for whom data were 
incomplete. A total of 3 241 children were therefore included in the 
study. There were 1 735 males (53.5%) and 1 506 females (46.5%) in 
the combined group (p=0.67). Of the children, 1 449 (44.7%) were 
aged 0 - 4 years, 962 (29.7%) 5 - 9 years, 808 (24.9%) 10 - 14 years 
and 22 (<1%) >14 years.
The median duration of follow-up was 17 months (range 1 day - 
26.4 years). Between 1 January 1987 and 31 December 2012 in both 
POUs, 1 551 children died from cancer or cancer-related infection or 
toxicity, giving an overall survival rate of 52.1% (median survival time 
45.7 months; 95% CI 29.9 - 61.5).
There was a 67.8% 1-year survival probability overall, with a 
median survival time of 9.3 months (95% CI 9.16 - 9.46). At 3 years 
this had changed to 56.4% (mean 22.9 months; 95% CI 22.4 - 23.5), 
and at 5 years to 53.8% (mean 34.8 months; 95% CI 33.9 - 35.8). 
Survival in all age groups was similar (p=0.43).
The five most common malignancies were the same in the two 
units and echoed the pattern of the SA Paediatric Tumour Registry. In 
both units lymphoma and nephroblastoma had the highest survival 
rates at 63.9% and 62.6%, respectively. Brain tumours had the lowest 
survival rate at 46.4% (Table 1).
The overall survival rates in the two units were similar (55.8% for 
Tygerberg Hospital, 50.6% for UHAC), with a combined overall rate 
of 52.1%.
Over half the children were black (n=1  886, 58.2%); followed 
by children of mixed ancestry (n=829, 25.6%) and white children 
(n=522, 16.1%) (ethnic group was known for 3 237 children). Cancer 
deaths were significantly more common among children in the 
former two groups than among white children, with black children 
having the shortest mean survival time (p<0.001). Survival was best 
Table 1. Prevalences and survival rates for the most common malignancies in children in two paediatric oncology units in SA 
Prevalence, n (%)
Malignancy
UHAC 
(N=2 284)
Tygerberg Hospital
(N=957)
Overall survival
n (%)
Median survival 
time (months)
Leukaemia (N=762) 490 (21.5) 272 (28.4) 372 (48.8) 46.5
Brain tumours (N=627) 437 (19.1) 190 (19.9) 291 (46.4) 18.2
Lymphoma (N=416) 282 (12.3) 134 (14.0) 266 (63.9) Mean 185.3* 
Nephroblastoma (N=329) 253 (11.1) 76 (7.9) 206 (62.6) 308.0
Retinoblastoma (N=182) 155 (6.8) 27 (2.8) 86 (47.3) 20.5
SA = South Africa; UHAC = Universitas Hospital Academic Complex.
*Median could not be calculated.
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among white children (62.8%), followed by 
children of mixed ancestry (53.8%) and 
black children (48.5%).
Similar differences in survival times 
were found for all the five most common 
malignancies, with black children doing 
consistently least well (Table 2).
The overall survival rate for nephro-
blastoma (all stages) was 62.6%. Survival 
for stage 1 nephroblastoma (81.1%) was the 
best of all the cancer types, with a mean 
of 220 months. Children with disease at 
the other stages did progressively worse, 
and survival for stage IV disease was only 
45.6%. Differences in survival times between 
the stages were highly significant (p<0.001). 
Black children presented predominantly with 
stage 3 and 4 disease. Analysis of survival 
between ethnic groups in different stages of 
disease demonstrated that black children had 
a significantly lower survival for all except 
stage 1 disease (log-rank test adjusted for 
stage, 7.4; p=0.02) (Table 3).
Patients with retinoblastoma were divided 
into two groups, depending on whether they 
had early or late-stage disease (early defined 
as limited local, intraorbital involvement, 
and late as involvement of bone marrow and/
or CSF, and/or with brain metastases). Early 
and late stages of retinoblastoma, occurring 
in equal numbers in both units (90 v. 92), 
had survival rates of 84.4% and 10.9%, 
respectively (overall survival 46.3%). Black 
children presented predominantly with late-
stage disease (56.9%), as opposed to 29% 
of children of mixed ancestry and 14.3% of 
white children. Although sample sizes were 
small, black children demonstrated a non-
significant trend towards a lower survival 
with stage 1 disease (82.3%) v. 100% of white 
and 86.4% of mixed-ancestry patients. 
Discussion
This is the first study of survival rates for 
children with cancer in SA. The results 
demonstrate that overall survival in 
childhood cancer remains low (52.1%) when 
compared with international data. In the 
past 40 years, the overall survival rate for 
childhood cancer in the UK has increased 
from 10% to nearly 90%.[6,10] The five most 
common malignancies in our cohort were 
similar to those commonly found in children 
in developed countries,[11] but survival rates 
were lower.
Black children consistently had worse 
survival rates than other ethnic groups for 
all the five most common malignancies and 
in almost all stages of nephroblastoma and 
retinoblastoma (Fig. 1). No differences in 
survival were found between the genders 
or between different age groups. Possible 
reasons for these differences in outcome for 
the different groups include late presentation, 
poor nutritional status, genetic factors and 
associated comorbidities (e.g. HIV infection 
and tuberculosis).[12] 
Children from low-income countries are 
often malnourished when a malignancy 
is diagnosed. Malnutrition in children 
with cancer renders them vulnerable to 
chemotherapy-related toxicity and infec-
tions, and ultimately increases the risk of 
death. Many studies document inadequate 
nutrition in black and coloured (mixed 
ancestry) children in SA, which is reflected 
in high rates of stunting and underweight.[13] 
Oelofse et al.[13] also found a substantially 
higher prevalence of micronutrient defic-
iencies among disadvantaged black and 
coloured infants in urban communities in 
the Western Cape than in other groups. 
All the above factors may result in a worse 
outcome for black children.
Table 2. Comparison of survival rates for the five most common childhood 
malignancies between three ethnic groups 
Children who survived, n/N (%)
Malignancy Black Mixed race White 
Leukaemia (N=762) 151/371 (40.7) 115/212 (54.2) 106/179 (59.2)
Brain tumours (N=627) 146/340 (42.9) 88/187 (47.1) 57/100 (57.0)
Lymphoma (N=415) 140/240 (58.3) 82/112 (73.2) 43/63 (68.3)
Nephroblastoma (N=329) 131/225 (58.2) 49/70 (70.0) 26/34 (76.5)
Retinoblastoma (N=182) 61/144 (42.2) 19/31 (61.3) 6/7 (85.7)
Table 3. Nephroblastoma survival according to ethnic group and stage 
Children who survived, n/N (%)
Nephroblastoma (N=321)* Black Mixed race White 
Stage 1 (N=95) 46/56 (82.1) 19/25 (76.0) 12/14 (85.7)
Stage 2 (N=42) 19/29 (65.5) 6/9 (66.7) 4/4 (100.0)
Stage 3 (N=92) 36/67 (53.7) 13/17 (76.5) 5/8 (62.5)
Stage 4 (N=79) 26/62 (41.3) 7/12 (58.3) 3/5 (60.0)
*Stage 5 (n=13) excluded. Data on stage missing n=8.
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Fig. 1. Comparative cancer survival in children according to ethnic group.
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During the study period, 23 HIV-infected children with a malig nancy 
presented to Tygerberg Hospital and 93 to UHAC, giving a prevalence 
of HIV-infected children with a malignancy of 2.4% in the former 
and 4.05% in the latter. Many social and demographic factors differ in 
the various ethnic groups, profoundly affecting survival rates. These 
include employment-related issues, transport-associated factors, 
caregivers, traditional attitudes to cancer and other ethnic beliefs.
The fact that most black children with nephroblastoma and 
retinoblastoma presented at an advanced stage of disease is attributable 
to the few points at which to access care in low socioeconomic areas, 
late referral from the primary health sector, and little knowledge 
about paediatric malignancy on the part of healthcare workers, 
parents and the community as a whole. A previous study in the 
Tygerberg Hospital referral area showed that a considerable delay in 
diagnosis could be attributed to physicians making a wrong initial 
diagnosis, delay in performing clinical tests, and delay in obtaining 
histopathological results.[14] Children in lower socioeconomic 
areas have less access to care than those in higher-income groups. 
Awareness campaigns in SA can improve knowledge about child hood 
malignancies and facilitate early diagnosis, particularly among these 
underprivileged children. However, stage of disease at presentation 
on its own cannot account for the differences in survival between the 
ethnic groups, black children showing significantly poorer survival 
at all stages of nephroblastoma (except stage 1) and retinoblastoma. 
It has been shown that children with cancer in low-income countries 
commonly fail to complete treatment.[15] Abandonment of therapy 
was not a significant factor in our study, as most of the patients from 
distant areas were provided with lodging by the CHOC (Childhood 
Cancer Foundation South Africa). Notably, in the cohort attending 
Tygerberg Hospital, with a geographically smaller referral area, no 
cases were lost to follow-up.
Differences in outcome between the various ethnic groups have 
also been demonstrated in SA children with Hodgkin’s lymphoma.[16] 
Further research into ethnic differences is needed to investigate such 
survival discrepancies.
Study limitations
There are number of limitations to this study. It was retrospective, 
so we were unable to ascertain the full impact of factors such as 
nutrition on survival. Data on nutritional status at presentation 
were not collected, and nutritional influence on survival is an aspect 
demanding further attention and research.
These results, from only two POUs, cannot be extrapolated to the 
broader SA population, as some units have only had a comprehensive 
tumour registry since 1987. It is estimated that two-thirds of 
childhood malignancies in SA are not reported to the registry, either 
because they are not diagnosed or because the patient is not referred 
to an appropriate treatment centre.[17] 
Sufficient staging information to perform a comparison was only 
available for two of the five most common malignancies. Further 
studies comparing staging information with survival for other solid 
tumours would be of interest.
Conclusion
Survival rates for childhood cancer in SA remain low when 
compared with international data. Children of black ethnic origin 
had significantly lower overall survival for all malignancies. Greater 
awareness of the danger signs of paediatric malignancy will foster 
earlier diagnosis of disease and lead to improved outcomes for all 
ethnic groups.
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